Under a tenth of patients who could benefit from obesity jabs including Wegovy have access to them, warns the World Health Organization as it issues its initial recommendations on the therapies.
Given in excess of 1,000,000,000 people worldwide currently obese, it is urging broader and more equitable availability to these injectable treatments.
According to forecasts, over two billion could be obese by 2030 unless action is taken.
"The latest guidance affirms that excess weight is a lifelong illness that can be managed with holistic and lifelong support," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are significant barriers to broad availability to the jabs that can aid individuals in losing considerable weight, says the agency.
GLP-1 Therapy Scarcity
Even under the current most favorable scenario, the production of these medications would only suffice for approximately 100 million people – less than 10% of eligible patients, as stated by the WHO.
The guideline calls on countries and companies to widen access, via approaches such as patent sharing.
A patent on the active ingredient – the primary component of Novo Nordisk's Wegovy – is due to expire in multiple countries in 2026.
The Way Weight-Loss Injections Function
The injections imitate a body's own hormone to reduce digestion speed, suppress the appetite and increase feelings of fullness so individuals eat less.
Individuals commonly see weight reduction after several weeks of beginning the regular doses.
Research points to people may regain a significant portion after a year of discontinuing the treatment, when their usual food cravings come back.
Being carrying excess weight elevates your chance for contracting medical conditions, like diabetes, cardiovascular issues, brain attack, and certain malignancies.
Obesity impacts people in all nations and was linked to millions of deaths worldwide in 2024, according to the WHO.
